These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9395815)

  • 1. Glycoprotein IIb/IIIa platelet receptor inhibitors: a new dimension in cardiology.
    Tan HC
    Ann Acad Med Singap; 1997 Jul; 26(4):481-8. PubMed ID: 9395815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IIb/IIIa receptor blockade in acute myocardial infarction.
    Ferguson JJ; Taqi K
    Am Heart J; 1999 Aug; 138(2 Pt 2):S164-70. PubMed ID: 10426877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of some cardiovascular risk factors on the expression of platelet glycoprotein IIb/IIIa receptors in patients with myocardial infarction treated with antiplatelet drugs under primary percutaneous coronary intervention.
    Konopka A; Spychalska J; Piotrowski W; Stepińska J
    Mol Diagn Ther; 2009 Dec; 13(6):375-82. PubMed ID: 19925035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
    Campbell KR; Ohman EM; Cantor W; Lincoff AM
    Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
    Starnes HB; Patel AA; Stouffer GA
    Drugs; 2011 Oct; 71(15):2009-30. PubMed ID: 21985168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
    Rasmussen S; Husted SE
    Ugeskr Laeger; 2001 Jan; 163(4):461-5. PubMed ID: 11218789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
    Lapchak PA; Araujo DM
    Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes.
    Kugelmass AD
    Curr Opin Hematol; 1997 Sep; 4(5):301-5. PubMed ID: 9288461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
    Dobesh PP; Latham KA
    Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
    Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
    Ann Emerg Med; 1998 Dec; 32(6):712-22. PubMed ID: 9832669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
    Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
    Eur J Emerg Med; 1998 Dec; 5(4):391-402. PubMed ID: 9919443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory?
    Harnick DJ; Vorchheimer DA
    Curr Cardiol Rep; 2001 Sep; 3(5):355-61. PubMed ID: 11504571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
    Liu F; Craft RM; Morris SA; Carroll RC
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.